Ipsen SA (IPSEY), a specialty-care biopharmaceutical company, Wednesday reported sales of 918.8 million euros for the first quarter, 11.7 percent higher than the same quarter a year ago.
For fiscal 2025, the company expects sales to grow 5 percent at constant currency.
In 2025, Ipsen anticipates key milestones including regulatory decision on Cabometyx in the European Union for advanced pancreatic and extra-pancreatic neuroendocrine tumors; readout of the Phase 2b study of fidrisertib in fibrodysplasia ossificans progressive; and Proof-of-concept data readout of long-acting neurotoxin, LANT.
For comments and feedback: editorial@rttnews.com